2,743
Views
5
CrossRef citations to date
0
Altmetric
Reproductive Medicine

FDA approved vs. Pharmacy compounded 17-OHPC—current issues for obstetricians to consider in reducing recurrent preterm birth

, &
Pages 1393-1401 | Received 22 Apr 2020, Accepted 07 Jun 2020, Published online: 30 Jun 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shiyu Zhang & Karen L. Rascati. (2021) Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention. Current Medical Research and Opinion 37:9, pages 1667-1675.
Read now

Articles from other publishers (4)

Jian Zhao, Jungang Zhang, Yan Xu, Juan Dong, Qichao Dong, Guoqiang Zhao & Ying Shi. (2023) Nanotechnological approaches for the treatment of placental dysfunction: recent trends and future perspectives. Nanomedicine.
Crossref
Mark I. Evans & David W. Britt. (2022) Resistance to Change. Reproductive Sciences 30:3, pages 835-853.
Crossref
Abdulaali R. Almutairi, Hadir I. Aljohani & Nouf S. Al-fadel. (2021) 17-Alpha-Hydroxyprogesterone vs. Placebo for Preventing of Recurrent Preterm Birth: A Systematic Review and Meta-Analysis of Randomized Trials. Frontiers in Medicine 8.
Crossref
Anjali Sharma, Nirnath Sah, Sujatha Kannan & Rangaramanujam M. Kannan. (2021) Targeted drug delivery for maternal and perinatal health: Challenges and opportunities. Advanced Drug Delivery Reviews 177, pages 113950.
Crossref